QualityDipStocks / Health Care · Health services
Fresenius Medical Care FMS
Outside our quality screen, so we don’t track its dips. It’s 16% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −16%
- Risk vs market
- Lowbeta 0.19
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for FMS: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much FMS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 2.4× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.19
- Volatility
- 31% vs 13% SPY
- Correlation SPY
- 0.08
- Correlation QQQ
- −0.03
How it ranks
Where FMS stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 3 measures
- Dividends + buybacks yield5.2% · cash paid out or used to retire shares, vs market capTop 25%of 1,836
- Revenue growth, last 12 months+1.5% · vs the 12 months beforeLowest 17%of 1,814
- Operating margin9.3% · of sales kept as operating profitLowest 40%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
FCF value $90.62
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ValuationP/E of 11.5× vs a 29.0× median for the 135 Health Care companies we cover.
ProfitabilityOperating margin widened to 9.3% in FY2025 from 7.0% in FY2023 (SEC filings).
GrowthDiluted EPS grew 84% in the last fiscal year, above the 8.2% median for the 103 Health Care companies we cover.
ValuationPrice / book of 0.8×, below the 5.2× median for the 217 Health Care companies we cover.
Top bearish points 5 of 5
GrowthSales grew only 0.4% a year from FY2022 to FY2025.
ProfitabilityReturn on equity is only 7% over the last 12 months.
ProfitabilityGross margin of 26%, below the 62% median for the 146 Health Care companies we cover.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; net debt 3.6× EBITDA (limit 3×).
RiskReports earnings Nov 3: results can move the price sharply and reset Market Value.
All fundamentals
P/E 11.5 · ROE 7% · Sales +2%
Valuation
- P/E
- 11.5×Health Care median 29.0×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 0.57×
- Price / book
- 0.85×
- Market cap
- $12.6Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $22.0B
- Sales growth, 12 months
- +1.5%vs the 12 months before
- Sales growth, 3 yrs
- +0.4%/yrfrom FY2022
- Diluted EPS, 12 months
- $3.36
- EPS growth, last FY
- +83.6%
- Net income, 12 months
- $1.1B
- Net income growth
- +82%12 months vs before
Profitability
- Gross margin
- 25.6%
- Operating margin
- 9.3%
- Net margin
- 5.0%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 7%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $1.8B
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 4.9×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $655M5.2% of market cap
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Fresenius Medical Care’s SEC filings, reported in EUR and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $2.0B · Sales +1%
- Free cash flow, 12 months$2.0B
- Free-cash-flow yield16.0%
- Free-cash-flow margin10%
- Gross margin26%
- Operating margin11%
- Return on invested capital7%
- Return on equity8%
- Sales growth (latest quarter vs year-ago quarter)+1%
- Net debt / EBITDA3.6×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $22.61
- 52-wk lowlowest close, 1 year$20.19−10.7%
- PriceMon Nov 2 close$22.61you are here
- 52-wk highhighest close, 1 year$26.84+18.7%
Momentum & 52-week range
RSI 54 · 5 days −0.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 3
- DateTue Nov 3, before the open
- Year-ago EPS$0.64
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
FMS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Fresenius Medical Care in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Health services
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.